Skip to main content
    E

    enGene Therapeutics Inc. (ENGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.89
    -0.52 (-21.58%)

    Market Cap: $161.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    enGene Therapeutics Inc. (ENGN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect enGene Therapeutics (ENGN) to earn -$1.59 per share in the fiscal year ending Oct 31, 2027, on revenue of $5.41M. Of 9 analysts, 3 rate the stock Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Oct 31, 2027 were revised up and 4 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.56, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.

    RatingAnalystsShare
    Strong Buy111.1%
    Buy222.2%
    Hold666.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending Oct 31, 2027
    -$1.59
    EPS consensus, revenue $5.41M
    Next report
    Dec 22, 2026
    Estimated
    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Oct 31, 2027-$1.59-$1.98 to -$1.037$5.41MN/A7

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Jan 31, 2027-$0.38-$0.44 to -$0.303

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Oct 31, 202734
    Quarter ending Jan 31, 202703

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Oct 31, 2027 has worsened from -$1.40.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Oct 31, 2027-$1.59-$1.51-$1.45-$1.44-$1.40N/A
    Quarter ending Jan 31, 2027-$0.38-$0.34-$0.34-$0.34-$0.31N/A

    Frequently Asked Questions About ENGN

    What is the ENGN stock forecast?

    Consensus analyst estimates put enGene Therapeutics's EPS at -$1.59 for the fiscal year ending Oct 31, 2027, on revenue of $5.41M. The consensus rating from 9 analysts is Hold.

    How do analysts rate ENGN stock?

    Of 9 analysts covering enGene Therapeutics, 1 rates it Strong Buy, 2 Buy, 6 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from ENGN next year?

    For the fiscal year ending Oct 31, 2027, the consensus EPS estimate is -$1.59, with estimates from -$1.98 to -$1.03 from 7 analysts.

    What revenue do analysts expect from enGene Therapeutics next year?

    For the fiscal year ending Oct 31, 2027, the consensus revenue estimate is $5.41M.

    How many analysts cover ENGN?

    9 analysts rate enGene Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Oct 31, 2027.